Stock comparison
Gyre Therapeutics
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GYRE
Gyre Therapeutics
Market cap
$587.78M
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GYRE | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 75B | IDXX |
| Benjamin Graham | 57D | 80A | IDXX |
| Philip Fisher | 60C | 75B | IDXX |
| Peter Lynch | 47D | 71B | IDXX |
| Joel Greenblatt | 44D | 83C | IDXX |
| Charlie Munger | 49D | 87A | IDXX |
| Terry Smith | 50C | 84A | IDXX |
Side-by-side metrics
| Metric | GYRE | IDXX |
|---|---|---|
| Market cap | $587.78M | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | 49.6x | 31.6x |
| ROIC (TTM) | 0.43% | 40.66% |
| Gross margin | 95.09% | 62.05% |
| Net margin | -5.37% | 24.63% |
| Revenue CAGR 5y | 99.65% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GYRE leads on
- P/E (TTM)-vs 39.0x+143%
- Debt / Equity0.0xvs 0.7x+99%
- Revenue CAGR 5y99.65%vs 7.56%+92%
- Gross margin95.09%vs 62.05%+35%
IDXX leads on
- Net margin24.63%vs -5.37%+122%
- ROIC (TTM)40.66%vs 0.43%+99%
- Market cap$44.12Bvs $587.78M+99%
- EV/EBIT31.6xvs 49.6x+36%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.